Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04919226
Title Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE (COMPOSE)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors ITM Solucin GmbH
Indications

gastrointestinal neuroendocrine tumor

pancreatic endocrine carcinoma

Therapies

Fluorouracil + Leucovorin + Oxaliplatin

177Lu-edotreotide

Everolimus

Capecitabine + Temozolomide

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP


No variant requirements are available.